media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

【EXPERT Q&A】Should this inquiry be prioritized for follow-up when the buyer in the pharmaceutical foreign trade scenario starts to request the COA, specification sheet and samples?

Drugdu.com expert’s response: In pharmaceutical foreign trade, after receiving an inquiry, the hardest part is often not figuring out how to reply, but determining which one deserves more of your time investment. Some buyers only send a one-line message saying “Please send price”, while others directly list product specifications, quantities and destination countries. There are also clients who, after two rounds of communication, start requesting COAs, Specifications, GMP documents, and even ask for samples. When several inquiries are laid out in front of you, the one with abundant information may not close a deal immediately, and the seemingly simple inquiry does not necessarily mean there is no procurement plan at all. To judge whether an inquiry is worth following up on with priority, you can refer to several specific behavioral signals from the buyer. Buyers asking about product details are usually more worthy of further exploration than those who only ...
- Source: drugdu
- 25
- August 12, 2026
Is Your Product Ready for Global Markets? Drugdu.com 10th Anniversary Overseas Promotion Readiness Program

Helping pharmaceutical and medical device companies better understand their overseas promotion readiness and next growth opportunities Expanding Overseas Markets Requires More Than Having a Good Product For pharmaceutical and medical device companies, entering global markets involves more than simply listing products online or finding potential buyers. Successful overseas promotion requires companies to present their capabilities clearly, communicate product value effectively, identify suitable markets, and build trust with international buyers. However, many companies still face challenges during their overseas expansion journey: They have strong products and manufacturing capabilities but are unsure which products should be prioritized for global promotion. They already have export experience but need clearer direction on which markets and channels to focus on. They have participated in exhibitions or invested in promotion but lack continuous feedback to optimize future strategies. Before investing more resources, companies need a clearer understanding of their current overseas promotion readiness. Drugdu.com 10th Anniversary ...
- Source: drugdu
- 35
- August 11, 2026
Medical Philippines

Organiser： Philippine Medical Association, Singapore Fireworks Exhibition Group Time：August 19-21, 2026 Address：Seashell Ln, Pasay, 1300 Metro Manila, Philippines Exhibition hall：SMX Convention Center Manila Product range: Medical Instruments and Equipment: Nursing assistive devices, diagnostic equipment, monitoring equipment, therapeutic equipment, laboratory analysis equipment, surgical specialized equipment, disinfection and sterilization equipment, traction and correction devices, rehabilitation physiotherapy equipment, medical vehicles, beds and tables, first aid and ambulance equipment, surgical devices, diagnostic equipment and supplies, analysis and control instruments, monitoring systems, surgical facilities, preventive medicine equipment, ophthalmic instruments and devices, otolaryngology equipment, dental supplies and equipment, radiological medical equipment, medical reagents and devices, prosthetics and rehabilitation aids, medical health products and supplies, etc. Medical Institution and Laboratory Technical Equipment: Laboratory instruments and equipment, laboratory furniture, laboratory automation and accessories, optical instrument equipment, medical experimental analysis and diagnostic instruments, biopharmaceutical instruments, cell biology instruments, biotechnology equipment, etc. Medical Materials: Artificial organs and implants, dressings ...
- Source: drugdu
- 40
- August 11, 2026
A Milestone in Pediatric Traditional Chinese Medicine Innovation! Jichuan Pharmaceutical’s Pediatric Laxative Granules Fill a Gap

Recently, Jichuan Pharmaceutical’s independently developed Class 1.1 innovative traditional Chinese medicine, Xiaotongbian Granules ( Pediatric Constipation Relief Granules) , officially received marketing approval from the National Medical Products Administration. This product fills the gap in the domestic market for traditional Chinese medicine specifically for children’s constipation , enriches the company’s product portfolio, and enhances its core competitiveness in the pediatric field. 01 Classic prescriptions from renowned doctors benefit a large number of children suffering from constipation Pediatric Constipation Relief Granules are the first innovative traditional Chinese medicine (TCM) drug approved for use in children under the new regulations and guidelines for innovative TCM drugs. It is the first innovative demonstration product in this field , filling a gap in domestic TCM treatments specifically for childhood constipation. The prescription originates from the clinical experience of pediatric expert Chen Yonghui (Capital Children’s Medical Center, Capital Medical University), and clinical trials have verified ...
- Source: drugdu
- 45
- August 10, 2026
Vonoprazan Fumarate Tablets Receive Drug Registration Certificate

On August 7th, Huahai Pharmaceutical(600521) issued an announcement stating that the company recently received the “Drug Registration Certificate” for vonoprazan fumarate tablets issued by the National Medical Products Administration. The drug is a tablet, with specifications of 20mg and 10mg, and is registered as a Class 4 chemical drug. Vonoprazan fumarate tablets are used for reflux esophagitis and can be used in combination with appropriate antibiotics to eradicate Helicobacter pylori. According to data from Menet.com, the domestic market sales of this drug are projected to reach approximately RMB 282 million in the first quarter of 2026. The company’s R&D investment in the vonoprazan fumarate tablets project is approximately RMB 4.22 million. In the first quarter of 2026, Huahai Pharmaceutical achieved revenue of 2.335 billion yuan and net profit attributable to the parent company of 404 million yuan. https://finance.eastmoney.com/a/202608073835322537.html
- Source: drugdu
- 47
- August 10, 2026
Lenvatinib Mesylate Capsules Receive Drug Registration Certificate

Nanfang Finance News, August 7th – Lu Kang PharmaceuticalThe company announced that it has received a Drug Registration Certificate for Lenvatinib Mesylate Capsules issued by the National Medical Products Administration. This product is used to treat patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy. https://finance.eastmoney.com/a/202608073835336556.html
- Source: drugdu
- 39
- August 10, 2026
Loxoprofen Sodium Patch Receives Drug Registration Certificate

　　Fuyuan Pharmaceutical(601089.SH) announced that it has received a Drug Registration Certificate for Loxoprofen Sodium Patches from the National Medical Products Administration, approving the production of the drug. This drug is used for anti-inflammatory and analgesic purposes for osteoarthritis, muscle pain, and swelling or pain caused by trauma. As of the date of the announcement, the company’s cumulative R&D investment in this drug is RMB 11.7065 million. Sales of Loxoprofen Sodium Patches in China’s three major terminal markets and six major markets are projected to reach approximately RMB 901 million by 2025. https://finance.eastmoney.com/a/202608073835312137.html
- Source: drugdu
- 41
- August 10, 2026
Subsidiary obtains drug registration certificate for injectable multivitamins (12)

　　Wei Xinkang(603676.SH) announced that its wholly-owned subsidiary, Baiyi Pharmaceutical, received approval from the National Medical Products Administration for injectable multivitamins .(12) Drug Registration Certificate. This drug is a Class 4 chemical drug and is considered to have passed the consistency evaluation. In 2025, the sales of this drug in domestic public medical institutions reached RMB 1.601 billion, and the cumulative R&D investment as of the end of July 2026 was RMB 11.3139 million. https://finance.eastmoney.com/a/202608073835199693.html
- Source: drugdu
- 41
- August 10, 2026
【EXPERT Q&A】How should a post-market supervision plan for in vitro diagnostic products be established under the EU IVDR regulation?

Drugdu.com expert’s response: Many IVD enterprises, when preparing for EU market compliance, tend to prioritize pre-market requirements such as CE certification, technical documentation and performance evaluation. However, regulatory obligations do not terminate once the product is placed on the market. In accordance with the EU IVDR, manufacturers are mandated to establish a Post-Market Surveillance (PMS) system to continuously collect post-launch real-world usage data, safety performance and potential risks of the device, and implement corresponding corrective actions based on the feedback. For IVD enterprises planning to access the EU market, the post-market surveillance plan shall be established as follows: 1. Define the objectives and scope of post-market surveillance in advance Prior to developing the PMS plan, the enterprise shall explicitly determine: The product portfolio covered by the surveillance scope; The sales territories of the products; Target user groups; Risk class of each product; Key issues requiring prioritized attention. Different IVD products ...
- Source: drugdu
- 42
- August 10, 2026
【EXPERT Q&A】What are the key requirements of the EU CE for the design and development control of medical devices?

Drugdu.com expert’s response: The key requirements of EU CE for medical device design and development control, which are centered on full-process compliance management, are mainly divided into the following modules: I. Planning Phase Before initiating the design, a complete project plan shall be formulated, clarifying project objectives, timelines, resource allocation, risk assessment and verification protocols. Accurately define the design inputs based on user requirements, EU regulations, safety standards and technical specifications, and specify core indicators such as the device’s performance, functions and safety. II. Implementation Phase Produce clear and actionable design deliverables, including product drawings, technical specifications, process flows and other contents to facilitate subsequent production and inspection. Organize regular cross-departmental design reviews to ensure that design outputs fully meet the requirements of design inputs, and simultaneously optimize design details. Implement full-process risk management, identify potential risks throughout the design, production and usage processes, and formulate corresponding risk control measures. ...
- Source: drugdu
- 57
- August 7, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.